CA2499273A1 - Inhalation compositions - Google Patents
Inhalation compositions Download PDFInfo
- Publication number
- CA2499273A1 CA2499273A1 CA002499273A CA2499273A CA2499273A1 CA 2499273 A1 CA2499273 A1 CA 2499273A1 CA 002499273 A CA002499273 A CA 002499273A CA 2499273 A CA2499273 A CA 2499273A CA 2499273 A1 CA2499273 A1 CA 2499273A1
- Authority
- CA
- Canada
- Prior art keywords
- dry powder
- microns
- diameter
- less
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract 26
- 239000002245 particle Substances 0.000 claims abstract 17
- 239000000843 powder Substances 0.000 claims abstract 13
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract 12
- 239000008101 lactose Substances 0.000 claims abstract 12
- 239000003814 drug Substances 0.000 claims abstract 6
- 229940112141 dry powder inhaler Drugs 0.000 claims abstract 2
- OBRNDARFFFHCGE-PERKLWIXSA-N (S,S)-formoterol fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 OBRNDARFFFHCGE-PERKLWIXSA-N 0.000 claims 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims 1
- 229960002848 formoterol Drugs 0.000 claims 1
- 229960000193 formoterol fumarate Drugs 0.000 claims 1
- 239000006185 dispersion Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Otolaryngology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides a dry powder inhalation composition comprising medicament particles and a mixture of lactose particles with a VMD of between about 70 and about 120 microns and a diameter of less than 250 microns, the mixture being characterized in that up to 96% by weight of the lactose particles are less than 150 microns in diameter and wherein up to 25% by weight of the lactose particles are less than 5 microns in diameter. The compositions provide for a more accurate, uniform and consistent dispersion when used with, for example, a multidose dry powder inhaler. Also disclosed are methods for use of the compositions of the invention.
Claims (12)
1. A dry powder inhalation composition comprising, (a) medicament particles, and (b) a mixture of lactose particles with a VMD of between about 70 and about microns and a diameter of less than 250 microns, said mixture characterized in that up to 96% by weight of the lactose particles are less than 150 microns in diameter and wherein up to 25% by weight of the lactose particles are less than 5 microns in diameter.
2. A dry powder inhalation composition according to Claim 1, wherein up to 85%
by weight of the lactose particles mixture is less than about 90 microns in diameter.
by weight of the lactose particles mixture is less than about 90 microns in diameter.
3. A dry powder inhalation composition according to Claim 1, wherein up to 37%
by weight of the lactose particles mixture is less than about 60 microns in diameter.
by weight of the lactose particles mixture is less than about 60 microns in diameter.
4. A dry powder inhalation composition according to Claim 1, wherein up to 35%
by weight of the lactose particles mixture is less than 30 microns in diameter.
by weight of the lactose particles mixture is less than 30 microns in diameter.
5. A dry powder inhalation composition according to Claim 1, wherein up to 31.5% by weight of the lactose particles mixture is less than 15 microns in diameter.
6. A dry powder inhalation composition according to Claim 1, wherein up to 30%
by weight of the lactose particles mixture is less than 10 microns in diameter.
by weight of the lactose particles mixture is less than 10 microns in diameter.
7. A dry powder inhalation composition according to Claim 1, wherein between 6.5 and 24.5% by weight of the lactose particles mixture is less than 5 microns in diameter.
8. A dry powder inhalation composition according to Claims 1 or 7, comprising up to 10% by weight of medicament particles.
9. A dry powder inhalation composition according to any one of the preceding Claims, wherein the medicament particles are formoterol or a pharmaceutically acceptable derivative thereof.
10. A dry powder inhalation composition according to any one of the preceding Claims, wherein the medicament particles are formoterol fumarate dehydrate.
11. A multidose dry powder inhaler comprising a dry powder inhalation composition according to any one of the preceding Claims.
12. A method for the administration of a particulate medicament, comprising inhalation from a MDPI of a dry powder inhalation composition according to Claims 1, 7, 9 or 10.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB02119513.9 | 2002-08-21 | ||
| GB02119513.7 | 2002-08-21 | ||
| GB0219513A GB0219513D0 (en) | 2002-08-21 | 2002-08-21 | Inhalation compositions including coarse carrier |
| PCT/US2003/026385 WO2004017914A2 (en) | 2002-08-21 | 2003-08-21 | Inhalation composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2499273A1 true CA2499273A1 (en) | 2004-03-04 |
| CA2499273C CA2499273C (en) | 2011-06-21 |
Family
ID=9942746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2499273A Expired - Fee Related CA2499273C (en) | 2002-08-21 | 2003-08-21 | Inhalation compositions |
Country Status (8)
| Country | Link |
|---|---|
| BR (1) | BRPI0313647A2 (en) |
| CA (1) | CA2499273C (en) |
| ES (1) | ES2371601T3 (en) |
| GB (1) | GB0219513D0 (en) |
| NO (1) | NO20051461L (en) |
| TN (1) | TNSN05047A1 (en) |
| WO (1) | WO2004017914A2 (en) |
| ZA (1) | ZA200502177B (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005102429A1 (en) | 2004-04-21 | 2005-11-03 | Innovata Biomed Limited | Inhaler |
| ES2717248T3 (en) | 2004-04-23 | 2019-06-20 | Cydex Pharmaceuticals Inc | Formulation of DPI containing sulfoalkyl ether cyclodextrin |
| GB0409197D0 (en) | 2004-04-24 | 2004-05-26 | Innovata Biomed Ltd | Device |
| ES2613391T3 (en) * | 2005-02-10 | 2017-05-24 | Glaxo Group Limited | Lactose manufacturing procedures using preclassification techniques and pharmaceutical formulations formed therefrom |
| US7629331B2 (en) | 2005-10-26 | 2009-12-08 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
| GB0605723D0 (en) | 2006-03-23 | 2006-05-03 | 3M Innovative Properties Co | Powder filling processes |
| WO2008134817A1 (en) * | 2007-05-03 | 2008-11-13 | The University Of Sydney | Composite carriers for dry powder inhalation therapy |
| TR201205852A2 (en) * | 2011-06-02 | 2012-12-21 | Bi̇lgi̇ç Mahmut | Improved new dry powder formulation. |
| TR201105367A2 (en) * | 2011-06-02 | 2012-12-21 | Bi̇lgi̇ç Mahmut | A dry powder formulation with improved flow properties. |
| GEP201706672B (en) | 2012-07-05 | 2017-05-25 | Arven Ilac Sanayi Ve Ticaret As | Dry powder inhaler compositions comprising long acting muscorinic antagonists |
| NZ703866A (en) | 2012-07-19 | 2016-05-27 | Adamis Pharmaceuticals Corp | Powder feeding apparatus |
| JP6251667B2 (en) | 2014-06-03 | 2017-12-20 | アサヒカルピスウェルネス株式会社 | Tablet-type immediate release preparation and method for producing the same |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ511527A (en) * | 1998-11-13 | 2002-10-25 | Jago Res A | Dry powder for inhalation |
| IL143576A0 (en) * | 1998-12-11 | 2002-04-21 | Pharmachemie Bv | Pharmaceutical preparation for inhalation of an opioid |
| CA2395653C (en) | 2000-10-12 | 2006-05-09 | Boehringer Ingelheim Pharma Kg | New inhalable powder containing tiotropium |
| UA75375C2 (en) | 2000-10-12 | 2006-04-17 | Boehringer Ingelheim Pharma | Method for producing powdery preparations for inhaling |
-
2002
- 2002-08-21 GB GB0219513A patent/GB0219513D0/en not_active Ceased
-
2003
- 2003-08-21 ES ES03751884T patent/ES2371601T3/en not_active Expired - Lifetime
- 2003-08-21 WO PCT/US2003/026385 patent/WO2004017914A2/en active Application Filing
- 2003-08-21 CA CA2499273A patent/CA2499273C/en not_active Expired - Fee Related
- 2003-08-21 BR BRPI0313647A patent/BRPI0313647A2/en active Search and Examination
-
2005
- 2005-02-18 TN TNP2005000047A patent/TNSN05047A1/en unknown
- 2005-03-15 ZA ZA200502177A patent/ZA200502177B/en unknown
- 2005-03-18 NO NO20051461A patent/NO20051461L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2499273C (en) | 2011-06-21 |
| NO20051461L (en) | 2005-05-20 |
| WO2004017914A8 (en) | 2005-07-07 |
| BRPI0313647A2 (en) | 2019-02-19 |
| ES2371601T3 (en) | 2012-01-05 |
| GB0219513D0 (en) | 2002-10-02 |
| WO2004017914A3 (en) | 2004-04-29 |
| WO2004017914A2 (en) | 2004-03-04 |
| ZA200502177B (en) | 2006-05-31 |
| TNSN05047A1 (en) | 2007-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN05047A1 (en) | Inhalation composition | |
| MX9404762A (en) | COMPOSITIONS FOR INHALATION AND PROCESS FOR ITS PREPARATION. | |
| CA2389349A1 (en) | Aerosol composition comprising formoterol | |
| WO2005079755A3 (en) | Interleukin-13 antagonist powders, spray-dried particles, and methods | |
| HUP0300593A2 (en) | Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets | |
| CA2395653A1 (en) | New inhalable powder containing tiotropium | |
| KR970704422A (en) | Pharmaceutical composition for administration | |
| AU2001236207A1 (en) | Powder formulation | |
| AU2001293899A1 (en) | Ihnalation particles incorporating a combination of two or more active ingredients | |
| TNSN05048A1 (en) | Inhalation compositions with high drug ratios | |
| CA2409660A1 (en) | Novel process | |
| MXPA05009629A (en) | Trospium containing compositions. | |
| WO2021028679A8 (en) | Pharmaceutical composition comprising ensifentrine | |
| WO2004012653A3 (en) | Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compostions thereof | |
| EP1599209A4 (en) | Inhalation composition | |
| DE60200202D1 (en) | Medicament containing a quinolone derivative and process for its preparation | |
| WO2006030301A8 (en) | Cilostazol- containing pharmaceutical composition based on particles of less than 50 micrometers | |
| MY140890A (en) | New tiotropium containing powder formulation for inhalation | |
| WO2002062317A3 (en) | Bimodal dry powder formulation for inhalation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20180821 |